KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Inventory: 2009-2025

Historic Inventory for Novavax (NVAX) over the last 4 years, with Sep 2025 value amounting to $13.5 million.

  • Novavax's Inventory rose 56.41% to $13.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.5 million, marking a year-over-year increase of 56.41%. This contributed to the annual value of $8.7 million for FY2024, which is 79.02% down from last year.
  • Per Novavax's latest filing, its Inventory stood at $13.5 million for Q3 2025, which was up 31.94% from $10.2 million recorded in Q2 2025.
  • Novavax's 5-year Inventory high stood at $256.3 million for Q2 2022, and its period low was $8.6 million during Q3 2024.
  • For the 3-year period, Novavax's Inventory averaged around $22.3 million, with its median value being $13.5 million (2025).
  • Per our database at Business Quant, Novavax's Inventory skyrocketed by 313.47% in 2022 and then crashed by 90.84% in 2023.
  • Quarterly analysis of 5 years shows Novavax's Inventory stood at $8.9 million in 2021, then surged by 313.47% to $36.7 million in 2022, then grew by 13.67% to $41.7 million in 2023, then slumped by 79.02% to $8.7 million in 2024, then spiked by 56.41% to $13.5 million in 2025.
  • Its last three reported values are $13.5 million in Q3 2025, $10.2 million for Q2 2025, and $10.3 million during Q1 2025.